15-ketoprostaglandin e2 profile

## 15-ketoprostaglandin E2 (15-keto PGE2)

**What is it?**

15-keto PGE2 is a **metabolite** of prostaglandin E2 (PGE2), a crucial signaling molecule in various physiological processes. It is formed by the enzymatic oxidation of PGE2, specifically at the 15-position.

**Why is it important for research?**

15-keto PGE2 is important for research due to its potential roles in **various biological functions and disease states**, and its association with **specific conditions and pathways**:

* **Inflammation:** 15-keto PGE2 is considered a **potent anti-inflammatory mediator**. While PGE2 itself is pro-inflammatory, its metabolite 15-keto PGE2 exhibits anti-inflammatory effects in various cell types and models. This has sparked research into its therapeutic potential in conditions like **arthritis and inflammatory bowel disease**.

* **Cancer:** Recent research suggests that 15-keto PGE2 may play a role in **tumorigenesis**, **tumor growth**, and **metastasis**. Its influence on cell proliferation, angiogenesis, and immune evasion in various cancer types is being investigated.

* **Cardiovascular disease:** 15-keto PGE2 exhibits **vasoconstrictive effects** and has been implicated in **atherosclerosis**. Its impact on blood pressure, platelet aggregation, and vascular smooth muscle cell function is being studied in relation to cardiovascular disease.

* **Neuroprotection:** 15-keto PGE2 has shown potential in **protecting neurons from damage** in models of stroke and neurodegenerative diseases. Its mechanisms of action, including anti-inflammatory and neurotrophic effects, are being investigated.

* **Renal function:** 15-keto PGE2 is known to influence **renal blood flow** and **glomerular filtration rate**. Research explores its potential role in regulating kidney function and its contribution to kidney disease pathogenesis.

**Research Focus:**

* **Mechanism of action:** Understanding how 15-keto PGE2 interacts with its receptors and signaling pathways is crucial to determine its precise role in various physiological and pathological processes.
* **Therapeutic potential:** Researchers are exploring 15-keto PGE2's potential as a therapeutic agent for various diseases, including inflammatory conditions, cancer, and neurodegenerative disorders.
* **Diagnostic marker:** 15-keto PGE2 levels in biological fluids might serve as a potential biomarker for certain diseases, providing insights into disease progression and response to treatment.

**Overall, 15-keto PGE2 is a promising molecule for research due to its diverse biological activities and potential therapeutic applications. As scientists continue to unravel its complex roles in various physiological and pathological processes, its significance in the field of biomedical research is expected to grow.**

15-ketoprostaglandin E2: metabolite of PGE2; RN given refers to (5Z,11alpha,13E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	5280719
CHEMBL ID	1447369
CHEBI ID	15547
SCHEMBL ID	11681397
MeSH ID	M0086608

Synonym
15-oxoprostaglandin e2
15-ketoprostaglandin e2
CHEBI:15547 ,
15-deoxy-15-oxo-prostaglandin e2
26441-05-4
(5z,13e)-11alpha-hydroxy-9,15-dioxoprosta-5,13-dienoic acid
9,15-dioxo-11r-hydroxy-5z,13e-prostadienoic acid
LMFA03010030
15-keto-prostaglandin e2
15-keto-pge2
SMP2_000019
C04707
(5z)-(15s)-11alpha-hydroxy-9,15-dioxoprosta-13-enoate
(5z,13e)-11alpha-hydroxy-9,15-dioxoprost-13-enoate
15-oxo-pge2
NCGC00161286-01
BML1-F11
(z)-7-[(1r,2r,3r)-3-hydroxy-5-oxo-2-[(e)-3-oxooct-1-enyl]cyclopentyl]hept-5-enoic acid
unii-2s0f1ftk13
prosta-5,13-dien-1-oic acid, 11-hydroxy-9,15-dioxo-, (5z,11alpha,13e)-
9,15-dioxo-11-hydroxyprosta-5,13-dienoic acid
2s0f1ftk13 ,
15-oxo-dinoprostone
15-keto pge2
dinoprostone impurity, 15-oxo-dinoprostone- [usp impurity]
15-dehydroprostaglandin e2
(z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-3-oxo-oct-1-enyl)-5-oxocyclopentyl)hept-5-enoic acid
prosta-5,13-dien-1-oic acid, 11-hydroxy-9,15-dioxo-, (5z,11.alpha.,13e)-
dinoprostone impurity f [ep impurity]
9,15-dioxo-11alpha-hydroxy-prosta-5z,13e-dien-1-oic acid
SCHEMBL11681397
CHEMBL1447369
YRTJDWROBKPZNV-KMXMBPPJSA-N
9,15-dioxo-11.alpha.-hydroxyprosta-5z,13e-dien-1-oic acid
HMS3648H19
15-keto prostaglandin e2
15-oxo-pge2-alpha
(5z,13e)-11-alpha-hydroxy-9,15-dioxoprost-5,13-dienoic acid
(5z)-(13e)-11-alpha-hydroxy-9,15-dioxoprosta-5,13-dienoate
(5z,13e)-11-alpha-hydroxy-9,15-dioxoprost-5,13-dienoate
15-keto-pge2-alpha
(5z)-(13e)-11-alpha-hydroxy-9,15-dioxoprosta-5,13-dienoic acid
Q27098095
sr-01000946431
SR-01000946431-1
DTXSID401317991
PD020583
HY-113205
CS-0059313
AT39645

Class	Description
prostaglandins E
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Eicosanoid metabolism via cyclooxygenases (COX)	1	37
Arachidonic acid (AA, ARA) oxylipin metabolism	0	76
Prostaglandin synthesis and regulation	0	8
Arachidonic acid metabolism via COX (Cyclooxygenase) pathway	0	35

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	100.0000	0.0032	45.4673	12,589.2998	AID2517
nuclear receptor ROR-gamma isoform 1	Mus musculus (house mouse)	Potency	1.1220	0.0079	8.2332	1,122.0200	AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	12 (33.33)	18.7374
1990's	4 (11.11)	18.2507
2000's	3 (8.33)	29.6817
2010's	15 (41.67)	24.3611
2020's	2 (5.56)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	37 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
hydrogen carbonate Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.	2.05	1	carbon oxoanion	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
niacinamide nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.	2.04	1	pyridine alkaloid; pyridinecarboxamide; vitamin B3	anti-inflammatory agent; antioxidant; cofactor; EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor; EC 3.5.1.98 (histone deacetylase) inhibitor; Escherichia coli metabolite; geroprotector; human urinary metabolite; metabolite; mouse metabolite; neuroprotective agent; Saccharomyces cerevisiae metabolite; Sir2 inhibitor
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	1.96	1	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	2.39	2	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.36	2	pyrazolidines; sulfoxide	uricosuric drug
cyclopentane Cyclopentanes: A group of alicyclic hydrocarbons with the general formula R-C5H9.. cyclopentanes : Cyclopentane and its derivatives formed by substitution.	2.03	1	cycloalkane; cyclopentanes; volatile organic compound	non-polar solvent
phenyl acetate phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.	2.03	1	benzenes; phenyl acetates
alkenes [no description available]	2.11	1
rosiglitazone [no description available]	2.46	2	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
prostaglandins b Prostaglandins B: Physiologically active prostaglandins found in many tissues and organs. They are potent pressor substances and have many other physiological activities.	2.38	2
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	3.08	5	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
prostaglandin d2 Prostaglandin D2: The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, platelet-activating-factor-inhibitory, and cytotoxic effects.. prostaglandin D2 : A member of the class of prostaglandins D that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9 and 15 and an oxo group at position 11 (the 5Z,9alpha,13E,15S- stereoisomer).	2.37	2	prostaglandins D	human metabolite; mouse metabolite
gw9662 2-chloro-5-nitrobenzanilide: pretreatment of peroxisome proliferator activated receptors with GW9662 results in the irreversible loss of ligand binding	2.15	1	benzamides
nadp [no description available]	2.68	3
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	4.92	36	prostaglandins E	human metabolite; mouse metabolite; oxytocic
dinoprost Dinoprost: A naturally occurring prostaglandin that has oxytocic, luteolytic, and abortifacient activities. Due to its vasocontractile properties, the compound has a variety of other biological actions.. prostaglandin F2alpha : A prostaglandins Falpha that is prosta-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15. It is a naturally occurring prostaglandin used to induce labor.	2.88	4	monocarboxylic acid; prostaglandins Falpha	human metabolite; mouse metabolite
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.03	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
leukotriene c4 Leukotriene C4: The conjugation product of LEUKOTRIENE A4 and glutathione. It is the major arachidonic acid metabolite in macrophages and human mast cells as well as in antigen-sensitized lung tissue. It stimulates mucus secretion in the lung, and produces contractions of nonvascular and some VASCULAR SMOOTH MUSCLE. (From Dictionary of Prostaglandins and Related Compounds, 1990). leukotriene C4 : A leukotriene that is (5S,7E,9E,11Z,14Z)-5-hydroxyicosa-7,9,11,14-tetraenoic acid in which a glutathionyl group is attached at position 6 via a sulfide linkage.	2.15	1	leukotriene	bronchoconstrictor agent; human metabolite; mouse metabolite
15-keto-13,14-dihydroprostaglandin e2 15-keto-13,14-dihydroprostaglandin E2: RN given refers to (5Z,11alpha)-isomer; structure in first source. 13,14-dihydro-15-oxo-prostaglandin E2 : The 13,14-dihydro derivative of 15-oxo-prostaglandin E2.	3.23	6	prostaglandins E
alprostadil [no description available]	2.36	2	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
prostaglandin a2 prostaglandin A2: RN given refers to (5Z,13E,15S)-isomer	2.03	1	prostaglandins A	human metabolite
15-ketoprostaglandin f2alpha [no description available]	1.98	1	prostaglandins Falpha
6-ketoprostaglandin f1 alpha 6-Ketoprostaglandin F1 alpha: The physiologically active and stable hydrolysis product of EPOPROSTENOL. Found in nearly all mammalian tissue.. 6-oxoprostaglandin F1alpha : A prostaglandin Falpha that is prostaglandin F1alpha bearing a keto substituent at the 6-position.	2.36	2	prostaglandins Falpha	human metabolite; mouse metabolite
6-ketoprostaglandin e1 6-ketoprostaglandin E1: potent direct dilator of pulmonary & systemic circulations of newborn lamb. 6-oxoprostaglandin E1 : A prostaglandin E that is prostaglandin E1 bearing a keto substituent at the 6-position.	1.96	1	prostaglandins E	metabolite; platelet aggregation inhibitor
jasmonic acid jasmonic acid: a derivative of alpha-linolenic acid that has a role in plant response to herbivory analogous to the role of prostanoids in inflammation in mammals;. jasmonic acid : An oxo monocarboxylic acid that is (3-oxocyclopentyl)acetic acid substituted by a (2Z)-pent-2-en-1-yl group at position 2 of the cyclopentane ring.	2.03	1	oxo monocarboxylic acid	jasmonates; plant metabolite
thromboxane b2 Thromboxane B2: A stable, physiologically active compound formed in vivo from the prostaglandin endoperoxides. It is important in the platelet-release reaction (release of ADP and serotonin).. thromboxane B2 : A member of the class of thromboxanes B that is (5Z,13E)-thromboxa-5,13-dien-1-oic acid substituted by hydroxy groups at positions 9, 11 and 15.	2.36	2	thromboxanes B	human metabolite; mouse metabolite
(2e)-decenal (2E)-decenal: structure in first source. (2E)-dec-2-enal : A dec-2-enal in which the olefinic double bond has E configuration.	2.11	1	2-decenal	alarm pheromone; mutagen; nematicide
11-hydroxy-5,8,12,14-eicosatetraenoic acid 11-hydroxy-5,8,12,14-eicosatetraenoic acid: RN given refers to cpd without isomeric designation	1.96	1
13-hydroperoxy-9,11-octadecadienoic acid 13-hydroperoxy-9,11-octadecadienoic acid: RN given refers to (E,Z)-isomer; RN for unspecified isomer not in Chemline 8/12/83. 13-HPODE : An HPODE (hydroperoxyoctadecadienoic acid) in which the double bonds are at positions 9 and 11 (E and Z geometry, respectively) and the hydroperoxy group is at position 13.	1.98	1	hydroperoxy polyunsaturated fatty acid; octadecadienoic acid
arachidonyl-coenzyme a arachidonoyl-CoA : An unsaturated fatty acyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of arachidononic acid.	1.98	1	arachidonoyl bioconjugate; unsaturated fatty acyl-CoA
ammonium sulfate Ammonium Sulfate: Sulfuric acid diammonium salt. It is used in CHEMICAL FRACTIONATION of proteins.. ammonium sulfate : An inorganic sulfate salt obtained by reaction of sulfuric acid with two equivalents of ammonia. A high-melting (decomposes above 280degreeC) white solid which is very soluble in water (70.6 g/100 g water at 0degreeC; 103.8 g/100 g water at 100degreeC), it is widely used as a fertilizer for alkaline soils.	1.98	1	ammonium salt; inorganic sulfate salt	fertilizer
methyl jasmonate [no description available]	2.03	1

Condition	Relationship Strength	Studies
Catarrh Inflammation of a mucous membrane with increased flow of mucous in humans or animals. Catarrh is used mostly in a historical context.	2.31	1
Common Cold A catarrhal disorder of the upper respiratory tract, which may be viral or a mixed infection. It generally involves a runny nose, nasal congestion, and sneezing.	2.31	1
Cancer of Colon [description not available]	2.15	1
Colonic Neoplasms Tumors or cancer of the COLON.	2.15	1
Acute Liver Injury, Drug-Induced [description not available]	2.15	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	2.15	1
C gattii Infection [description not available]	2.21	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	3.02	4
Cryptococcosis Fungal infection caused by genus CRYPTOCOCCUS.	2.21	1
Diabetes Mellitus, Adult-Onset [description not available]	2.21	1
Insulin Sensitivity [description not available]	2.21	1
Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.	2.21	1
Insulin Resistance Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.	2.21	1
Disease Exacerbation [description not available]	2.21	1
Breast Cancer [description not available]	2.21	1
Breast Neoplasms Tumors or cancer of the human BREAST.	2.21	1
Hepatocellular Carcinoma [description not available]	2.1	1
Cancer of Liver [description not available]	2.1	1
Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.	2.1	1
Liver Neoplasms Tumors or cancer of the LIVER.	2.1	1
Cholangiocellular Carcinoma [description not available]	2.08	1
Bile Duct Cancer [description not available]	2.08	1
Bile Duct Neoplasms Tumors or cancer of the BILE DUCTS.	2.08	1
Cholangiocarcinoma A malignant tumor arising from the epithelium of the BILE DUCTS.	7.08	1
Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).	2.08	1
Lung Adenocarcinoma [description not available]	2.11	1
Adenocarcinoma, Basal Cell [description not available]	2.11	1
Cancer of Lung [description not available]	2.11	1
Adenocarcinoma of Lung A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.	2.11	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.11	1
Lung Neoplasms Tumors or cancer of the LUNG.	2.11	1
Cancer of Pancreas [description not available]	2.13	1
Carcinoma, Ductal, Pancreatic [description not available]	2.13	1
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	2.13	1
Carcinoma, Pancreatic Ductal Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.	2.13	1
Cystic Fibrosis of Pancreas [description not available]	2.46	2
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	2.46	2
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.36	2
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.99	1
Endomyometritis Inflammation of both the ENDOMETRIUM and the MYOMETRIUM, usually caused by infections after a CESAREAN SECTION.	1.97	1
Equine Diseases [description not available]	1.97	1
Endometritis Inflammation of the ENDOMETRIUM, usually caused by intrauterine infections. Endometritis is the most common cause of postpartum fever.	1.97	1
Acute Myelogenous Leukemia [description not available]	1.97	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	1.97	1
Erythema Redness of the skin produced by congestion of the capillaries. This condition may result from a variety of disease processes.	1.96	1

15-ketoprostaglandin e2

Description

Cross-References

Synonyms (50)

Drug Classes (1)

Pathways (4)

Protein Targets (2)

Potency Measurements

Research

Studies (36)

Market Indicators

Research Demand Index: 11.21

Study Types